 |
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Hormone/growth factor
|
PDB id
|
|
|
|
1ijt
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
|
 |
|
 |
|
|
Gene Ontology (GO) functional annotation
|
|
|
|
 |
 |
 |
|
 |
 |
 |
 |
|
 |
|
Biochemical function
|
growth factor activity
|
1 term
|
 |
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
Mol Cell Biol
21:5946-5957
(2001)
|
|
PubMed id:
|
|
|
|
|
| |
|
Identification of receptor and heparin binding sites in fibroblast growth factor 4 by structure-based mutagenesis.
|
|
P.Bellosta,
A.Iwahori,
A.N.Plotnikov,
A.V.Eliseenkova,
C.Basilico,
M.Mohammadi.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Fibroblast growth factors (FGFs) comprise a large family of multifunctional,
heparin-binding polypeptides that show diverse patterns of interaction with a
family of receptors (FGFR1 to -4) that are subject to alternative splicing. FGFR
binding specificity is an essential mechanism in the regulation of FGF signaling
and is achieved through primary sequence differences among FGFs and FGFRs and
through usage of two alternative exons, IIIc and IIIb, for the second half of
immunoglobulin-like domain 3 (D3) in FGFRs. While FGF4 binds and activates the
IIIc splice forms of FGFR1 to -3 at comparable levels, it shows little activity
towards the IIIb splice forms of FGFR1 to -3 as well as towards FGFR4. To begin
to explore the structural determinants for this differential affinity, we
determined the crystal structure of FGF4 at a 1.8-A resolution. FGF4 adopts a
beta-trefoil fold similar to other FGFs. To identify potential receptor and
heparin binding sites in FGF4, a ternary FGF4-FGFR1-heparin model was
constructed by superimposing the FGF4 structure onto FGF2 in the
FGF2-FGFR1-heparin structure. Mutation of several key residues in FGF4, observed
to interact with FGFR1 or with heparin in the model, produced ligands with
reduced receptor binding and concomitant low mitogenic potential. Based on the
modeling and mutational data, we propose that FGF4, like FGF2, but unlike FGF1,
engages the betaC'-betaE loop in D3 and thus can differentiate between the IIIc
and IIIb splice isoforms of FGFRs for binding. Moreover, we show that FGF4 needs
to interact with both the 2-O- and 6-O-sulfates in heparin to exert its optimal
biological activity.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
J.W.Park,
O.C.Jeon,
S.K.Kim,
T.A.Al-Hilal,
S.J.Jin,
H.T.Moon,
V.C.Yang,
S.Y.Kim,
and
Y.Byun
(2010).
High antiangiogenic and low anticoagulant efficacy of orally active low molecular weight heparin derivatives.
|
| |
J Control Release, 148,
317-326.
|
 |
|
|
|
|
 |
H.P.Makarenkova,
M.P.Hoffman,
A.Beenken,
A.V.Eliseenkova,
R.Meech,
C.Tsau,
V.N.Patel,
R.A.Lang,
and
M.Mohammadi
(2009).
Differential interactions of FGFs with heparan sulfate control gradient formation and branching morphogenesis.
|
| |
Sci Signal, 2,
ra55.
|
 |
|
|
|
|
 |
Y.Mayshar,
E.Rom,
I.Chumakov,
A.Kronman,
A.Yayon,
and
N.Benvenisty
(2008).
Fibroblast growth factor 4 and its novel splice isoform have opposing effects on the maintenance of human embryonic stem cell self-renewal.
|
| |
Stem Cells, 26,
767-774.
|
 |
|
|
|
|
 |
H.Zander,
U.Reineke,
J.Schneider-Mergener,
and
A.Skerra
(2007).
Epitope mapping of the neuronal growth inhibitor Nogo-A for the Nogo receptor and the cognate monoclonal antibody IN-1 by means of the SPOT technique.
|
| |
J Mol Recognit, 20,
185-196.
|
 |
|
|
|
|
 |
R.Goetz,
A.Beenken,
O.A.Ibrahimi,
J.Kalinina,
S.K.Olsen,
A.V.Eliseenkova,
C.Xu,
T.A.Neubert,
F.Zhang,
R.J.Linhardt,
X.Yu,
K.E.White,
T.Inagaki,
S.A.Kliewer,
M.Yamamoto,
H.Kurosu,
Y.Ogawa,
M.Kuro-o,
B.Lanske,
M.S.Razzaque,
and
M.Mohammadi
(2007).
Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members.
|
| |
Mol Cell Biol, 27,
3417-3428.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
M.Mohammadi,
S.K.Olsen,
and
O.A.Ibrahimi
(2005).
Structural basis for fibroblast growth factor receptor activation.
|
| |
Cytokine Growth Factor Rev, 16,
107-137.
|
 |
|
|
|
|
 |
M.J.García-García,
and
K.V.Anderson
(2003).
Essential role of glycosaminoglycans in Fgf signaling during mouse gastrulation.
|
| |
Cell, 114,
727-737.
|
 |
|
|
|
|
 |
Y.Luo,
H.H.Cho,
and
W.L.McKeehan
(2003).
Biospecific extraction and neutralization of anticoagulant heparin with fibroblast growth factors (FGF).
|
| |
J Pharm Sci, 92,
2117-2127.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
|